• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioNTech SE - American Depositary Shares (NQ:BNTX)

    108.80 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,005
    Open 108.80
    Bid (Size) 108.80 (200)
    Ask (Size) 109.94 (700)
    Prev. Close 108.80
    Today's Range 108.80 - 108.80
    52wk Range 81.20 - 124.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
    As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Initial Public Offering

    Performance

    YTD
    +12.5%
    +12.5%
    1 Month
    -8.8%
    -8.8%
    3 Month
    +5.5%
    +5.5%
    6 Month
    +6.7%
    +6.7%
    1 Year
    -4.6%
    -4.6%

    More News

    Read More
    News headline image
    Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
    Via Finterra
    Topics Economy Intellectual Property
    BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio ↗
    Via Stocktwits
    News headline image
    Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology
    Via Finterra
    Topics Artificial Intelligence Initial Public Offering Intellectual Property
    News headline image
    BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    2 Biotech Stocks Set to Rebound in 2026 ↗
    Via The Motley Fool
    News headline image
    Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse
    Via Finterra
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
    From USA News Group
    Via GlobeNewswire
    News headline image
    Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
    Via Finterra
    Topics Initial Public Offering Intellectual Property
    Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It ↗
    Via Chartmill
    Topics Government
    News headline image
    The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
    Via MarketMinute
    Topics Economy Intellectual Property World Trade
    News headline image
    BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
    Via PredictStreet
    Topics Initial Public Offering Intellectual Property
    News headline image
    Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
    Via PredictStreet
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗
    Via Stocktwits
    Topics Supply Chain
    News headline image
    Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery
    Via PredictStreet
    Topics Initial Public Offering
    News headline image
    The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
    Via PredictStreet
    Topics Economy Intellectual Property
    News headline image
    Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive
    Via PredictStreet
    Topics Earnings Initial Public Offering Intellectual Property
    News headline image
    BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
    From BioNTech SE
    Via GlobeNewswire

    Frequently Asked Questions

    Is BioNTech SE - American Depositary Shares publicly traded?
    Yes, BioNTech SE - American Depositary Shares is publicly traded.
    What exchange does BioNTech SE - American Depositary Shares trade on?
    BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for BioNTech SE - American Depositary Shares?
    The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
    What is the current price of BioNTech SE - American Depositary Shares?
    The current price of BioNTech SE - American Depositary Shares is 108.80
    When was BioNTech SE - American Depositary Shares last traded?
    The last trade of BioNTech SE - American Depositary Shares was at 02/26/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.